Skip to main content
Clinical Trials/NCT00852462
NCT00852462CompletedPhase 2

Lung Cancer Symptom Assessment and Management Intervention

Dana-Farber Cancer Institute4 sites in 1 country179 target enrollmentStarted: May 2008Last updated:
Conditions

Trial Snapshot

Phase
Phase 2
Status
Completed
Enrollment
179
Locations
4
Primary Endpoint
% completion of intervention use and adherence to suggested symptom management strategies.

Study Overview

Brief Summary

The purpose of this study is to develop and test the usability of a computerized symptom assessment and management intervention system in a laboratory setting (phase I) and its feasibility in a clinical setting in a group randomized trial (phase II).

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Supportive Care
Masking
None

Eligibility Criteria

Ages
21 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • HCPs: attending physician, thoracic medical oncologist, expected to work in the setting for at least 2 years.
  • Patients: 21 years of age or older; diagnosis of Stage IIIA, IIIB, IV non-small cell lung cancer OR limited or extensive stage small cell lung cancer; receiving care in the out-patient setting; receiving treatment with chemotherapy +/- additional therapies; English speaking.

Exclusion Criteria

  • Patients: Any patient who needs emergent care, routine visits scheduled less than once a month

Outcomes

Primary Outcomes

% completion of intervention use and adherence to suggested symptom management strategies.

Time Frame: 2 years

Secondary Outcomes

  • Health-related quality of life(6 months)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Mary E. Cooley, Phd

Nurse Scientist

Dana-Farber Cancer Institute

Study Sites (4)

Loading locations...

Similar Trials

Lung Cancer Symptom Assessment and... | Clinical Trial